Last reviewed · How we verify
TACE regimen
TACE (transarterial chemoembolization) is a locoregional therapy that delivers chemotherapy directly to hepatocellular carcinoma tumors via the hepatic artery while simultaneously blocking blood supply to the tumor.
TACE (transarterial chemoembolization) is a locoregional therapy that delivers chemotherapy directly to hepatocellular carcinoma tumors via the hepatic artery while simultaneously blocking blood supply to the tumor. Used for Hepatocellular carcinoma, intermediate stage (BCLC stage B), Hepatocellular carcinoma, advanced stage (BCLC stage C) as bridge or palliative therapy.
At a glance
| Generic name | TACE regimen |
|---|---|
| Also known as | Transarterial Chemoembolization, TAE, Trans-Arterial Chemoembolization, Atezolizumab, Bevacizumab |
| Sponsor | Sun Yat-sen University |
| Drug class | Locoregional chemotherapy/embolization procedure |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TACE combines chemotherapy infusion with embolization of the feeding blood vessel to the tumor, creating a dual mechanism of drug delivery and ischemic necrosis. The procedure selectively targets tumor vasculature while minimizing systemic exposure. This approach is particularly effective for intermediate-stage hepatocellular carcinoma where the tumor burden is too extensive for surgical resection but the liver function remains adequate.
Approved indications
- Hepatocellular carcinoma, intermediate stage (BCLC stage B)
- Hepatocellular carcinoma, advanced stage (BCLC stage C) as bridge or palliative therapy
Common side effects
- Post-embolization syndrome (fever, abdominal pain, nausea)
- Hepatic dysfunction/elevated transaminases
- Ascites
- Encephalopathy
- Bleeding/hematoma at puncture site
Key clinical trials
- IIT2025-03-YANG-LIFT-HCC (PHASE2)
- TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens (PHASE2)
- Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning (NA)
- Adjuvant TACE in HCC With High-risk Recurrence Factors (PHASE3)
- Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial (PHASE2)
- Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment (NA)
- A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
- A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TACE regimen CI brief — competitive landscape report
- TACE regimen updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI